The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion

Ahmadi, Amir Ali; Chuo, Jean Y.; Banashkevich, A.; Patrick, Ellis; Maberley, David

doi:10.3129/i09-040

Cited by 20 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also indicated for the treatment of CNV associated with entities such as high myopia,16,17 macular edema associated with vascular occlusion18 or diabetes mellitus,19 and premature retinopathy of prematurity 20…”

Section: Discussionmentioning

confidence: 99%

Bilateral choroidal neovascularization associated with optic nerve head drusen treated by antivascular endothelial growth factor therapy

Delás¹,

Almudí²,

Carreras³

et al. 2012

OPTH

View full text Add to dashboard Cite

ObjectiveTo report a good clinical outcome in a patient with bilateral choroidal neovascularization (CNV) associated with optic nerve head drusen (ONHD) treated with intravitreal ranibizumab injection.MethodsA 12-year-old girl was referred for loss of right eye vision detected in a routine check-up. Best-corrected visual acuity (BCVA) was hand movements in the right eye and 0.9 in the left eye. Funduscopy revealed the presence of superficial and buried bilateral ONHD, which was confirmed by ultrasonography and computed tomography, and the study was completed with perimetry. The presence of bilateral CNV, active in the right eye, was observed and subsequently confirmed using fluorescein angiography and optical coherence tomography.ResultsTreatment with two consecutive injections of intravitreal ranibizumab resulted in inactivation of the neovascular membrane with subretinal fluid reabsorption and improved right eye BCVA. After 12 months’ follow-up, this was 20/60 and stable.ConclusionAlthough there are no published studies of safety in children, antiangiogenic therapy for CNV secondary to ONHD may be useful and safe. A search of the literature produced only one previously reported case of ONHD-associated CNV treated with antivascular endothelial growth factor alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Bilateral choroidal neovascularization associated with optic nerve head drusen treated by antivascular endothelial growth factor therapy

Delás¹,

Almudí²,

Carreras³

et al. 2012

OPTH

View full text Add to dashboard Cite

show abstract

“…One of the main mediators exacerbating macular edema is vascular endothelial growth factor (VEGF) [2]. Bevacizumab is an off-label anti-VEGF agent used in ophthalmology practice, and intravitreal injection of bevacizumab (IVB) results in prompt reduction of macular edema associated with recovery of vision in eyes with symptomatic macular edema secondary to BRVO [3][4][5][6][7][8][9][10]. These effects seem to be equal or superior to those of other treatments, including laser photocoagulation [11] and intravitreal triamcinolone acetonide [12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The dosage varies between 1 and 2.5 mg, there are no different outcomes [39,40,41,42,43,44,45,46,47,48]. The Pan-American Collaborative Retina Study group concluded that intravitreal injections of bevacizumab at doses up to 2.5 mg were more effective in improving VA and reducing macular edema at 6 months (compared to 1.25 mg), but the study had no control group [44].…”

Section: Treatmentmentioning

confidence: 99%

Retinal Vein Occlusion: Current Treatment

Lattanzio¹,

Gimeno

Parodi³

et al. 2010

Ophthalmologica

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) is a pathology noted for more than 150 years. Although a lot has been written on the matter, it is still a frequent condition with multifactorial etiopathogenesis with many unclear aspects. The RVO pathogenesis has varied systemic and local implications that make it difficult to elaborate treatment guidelines. The management of the patient with RVO is very complex and a multidisciplinary approach is required in order to identify and correct the associated risk factors. Laser therapy remains the gold standard in RVO, but only modest functional improvement has been shown in branch retinal occlusion forms. Multicenter studies of intravitreal drugs present them as an option to combine with laser. Anti-vascular endothelial growth factor, corticosteroids and sustained-release implants are the future weapons to stop disease progression and get a better visual outcome. Consequently, it is useful to clarify some aspects of the pathology that allow a better patient management.

show abstract

The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion

Cited by 20 publications

References 39 publications

Bilateral choroidal neovascularization associated with optic nerve head drusen treated by antivascular endothelial growth factor therapy

Bilateral choroidal neovascularization associated with optic nerve head drusen treated by antivascular endothelial growth factor therapy

Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab

Retinal Vein Occlusion: Current Treatment

Contact Info

Product

Resources

About